Introduction {#s1}
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death in the world [@pone.0056153-ElSerag1]--[@pone.0056153-ElSerag2]. As for other cancers, the etiology of HCC is multifactorial and progresses through multiple stages [@pone.0056153-Romeo1]. This multistep process may be divided into chronic liver injury, inflammation, cell death, cirrhosis, regeneration, DNA damage, dysplasia and finally HCC. Different lesions have been considered pre-neoplastic in regard to the development of HCC. For instance, cirrhotic liver contains regenerative nodules and like HCC may contain dysplastic nodules [@pone.0056153-Schafer1], [@pone.0056153-Kim1]. The principal risk factor for the development of HCC is hepatitis B virus (HBV) [@pone.0056153-Block1], [@pone.0056153-Buendia1] **,** followed by hepatitis C virus (HCV) infection [@pone.0056153-Koike1]. Non viral causes are less frequent and include toxins and drugs (e.g., alcohol, aflatoxins, microcystin, anabolic steroids), metabolic liver diseases (e.g., hereditary haemochromatosis, a1-antitrypsin deficiency), steatosis [@pone.0056153-Ohata1] and non-alcoholic fatty liver disease [@pone.0056153-Brunt1], [@pone.0056153-Davila2]. In general, HCCs are more prevalent in men than in women and the incidence increases with age.

The molecular mechanism underlying HCC is currently unknown. Activation of cellular oncogenes, inactivation of tumor suppressor genes, over-expression of growth factors, possibly telomerase activation and DNA mismatch repair defects may contribute to the development of HCC. Alterations in gene expression patterns accompanying different stages of growth, disease initiation, cell cycle progression, and responses to environmental stimuli provide important clues to these complex process [@pone.0056153-AlSukhun1], [@pone.0056153-Theodorescu1]. In addition to primary HCC, metastatic liver disease often occurs. Metastases most often derive from gastrointestinal organs, primarily colon and rectum, though they can occur from primaries throughout the body [@pone.0056153-Groen1] **.** These cancers can be treated using routine therapies relevant to the primary such as chemotherapy, radiotherapy, surgical resection, liver transplantation, chemo-embolization, cryosurgery or combination therapy [@pone.0056153-Yamane1]. The characterization of genes that are differentially expressed during tumorigenesis is an important step toward the identification of the biological steps involved in the transformation process. Studies examining the gene expression of metastatic liver tumors and HCC in parallel with paired non-cancerous liver tissues might yield important insights by identifying genes not expressed in normal liver and are switched on in tumors and vice versa. Such studies should also lead to the identification of genes that are expressed in tumors at different stages and never in non cancerous liver tissue.

The present study assessed the expression profile of 18 HCV-related primary HCCs and their corresponding HCV-positive non-HCC counterpart, 1 HCV-positive liver sample without the corresponding HCC tissue, 14 gastrointestinal liver metastases and their corresponding non cancerous tissue and 6 liver biopsies from patients with benign pathologies and normal liver by use of high-density oligonucleotide arrays. This represents an independent study from a previous study performed by our group [@pone.0056153-DeGiorgi1]. An HCC-specific molecular signature set was identified that may enhance conventional pathologic assessment and may provide a tool for prognostic purposes, as well as identify targets for new therapeutic strategies.

Materials and Methods {#s2}
=====================

Patient and Tissue Samples {#s2a}
--------------------------

A total of 102 liver human samples have been analyzed. Thirty one samples were used to define the signature genes in the first group of samples represented by a subset of samples from 19 patients profiled and reported in a previous study of molecular classification of HCV-related hepatocellular carcinoma [@pone.0056153-DeGiorgi1]. An independent set of 71 liver biopsies has been used to define/evaluate the identified liver cancer signature ([Figure 1](#pone-0056153-g001){ref-type="fig"}).

![Study design.\
Gene signature distinguishing the different pathological stage of liver disease and potential molecular progression markers was defined in the first dataset (left panel) and defined/evaluated in the independent second dataset (right panel).](pone.0056153.g001){#pone-0056153-g001}

Liver biopsies from 19 HCV-positive HCCs, 14 metastases from distant primary and 6 HCV-negative control samples from healthy donors obtained during laparoscopic cholecystectomy were obtained with informed consent at the liver unit of the INT "Pascale", Naples. In addition from each of the HCV-positive HCC and metastatic patients a paired liver biopsy from non-adjacent, non-tumor containing liver was obtained. All liver biopsies were stored in RNA Later at −80C° (Ambion, Austin,TX). Confirmation of the histopathological nature of the biopsies was performed by the Pathology lab at INT before processing samples for RNA extraction. The non-HCC tissues from HCV-positive patient represented a heterogeneous sample consistent with the prevalent liver condition of each subject (ranging from persistent HCV-infection to cirrhotic lesions). One HCC sample, was shown to be mainly cirrhotic tissue and removed from the analysis. Furthermore, laboratory analysis confirmed that the 6 controls were seronegative for HCV antibodies.

RNA Isolation, cDNA Synthesis, in vitro Transcription and aRNA Labeling {#s2b}
-----------------------------------------------------------------------

Samples were homogenized in disposable tissue grinders (Kendall, Precision). Total RNA was extracted by TRIzol solution (Life Technologies, Rockville, MD), and purity of the RNA preparation was verified evaluating the 260∶280 nm ratio of the spectrophotometric reading with NanoDrop (Thermo Fisher Scientific, Waltham, MA). Moreover, the integrity of extracted RNA was evaluated by Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), analyzing the presence of 28S and 18S ribosomal RNA bands and verifying that the 28S/18S rRNA intensity ratio was equal or close to 1.5. In addition, phenol contamination was evaluated considering acceptable a 260∶230 nm OD ratio within a 2.0--2,2 range.

Double-stranded complementary DNA (cDNA) was prepared from 3 µg of total RNA (T-RNA) in 9 µl DEPC -treated H~2~O using the Super script II Kit (Invitrogen) with a T7-(dT15) oligonucleotide primer. cDNA synthesis was completed at 42°C for 1 h. Full-length dsDNA was synthesized incubating the produced cDNA with 2 U of RNase-H (Promega) and 3 µl of Advantage cDNA Polymerase Mix (Clontech), in Advantage PCR buffer (Clontech), in presence of 10 mM dNTP and DNase-free water. dsDNA was extracted with phenol--chloroform--isoamyl, precipitated with ethanol in the presence of 1 µl linear acrylamide (0.1 µg/µl, Ambion, Austin, TX) and aRNA (amplified-RNA) was synthesized using Ambion's T7 MegaScript in Vitro Transcription Kit (Ambion, Austin, TX). aRNA recovery and removal of template dsDNA was achieved by TRIzol purification. For the second round of amplification, aliquots of 1 µg of the aRNA were reverse transcribed into cDNA using 1 µl of random hexamer under the conditions used in the first round. Second-strand cDNA synthesis was initiated by 1 µg oligo-dT-T7 primer and the resulting dsDNA was used as template for in vitro transcription of aRNA in the same experimental conditions as for the first round [@pone.0056153-Wang1]. 6 µg of this aRNA was used for probe preparation, in particular test samples were labeled with USL-Cy5 (Kreatech) and pooled with the same amount of reference sample (control donor peripheral blood mononuclear cells, PBMC, seronegative for anti-hepatitis C virus (HCV) antibodies ) labeled with USL-Cy3 (Kreatech).The two labeled aRNA probes were separated from unincorporated nucleotides by filtration, fragmented, mixed and co-hybridized to a custom-made 36K oligoarrays at 42C°for 24 h. The oligo-chips were printed at the Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health (Bethesda, MD). After hybridization the slides were washed with 2xSSC/0.1%SDS for 1 min, 1xSSC for 1 min, 0.2xSSC for 1 min, 0.05×SSC for 10 sec., and dried by centrifugation at 800 g for 3 minutes at RT.

Data Analysis {#s2c}
-------------

Hybridized arrays were scanned at 10-µm resolution with a GenePix 4000 scanner (Axon Instruments) at variable photomultiplier tube (PMT) voltage to obtain maximal signal intensities with less than 1% probe saturation. Image and data files were deposited at microarray data base (mAdb) at <http://madb.nci.nih.gov> and retrieved after median centered, filtering of intensity (\>200) and spot elimination. Data were further analyzed using Cluster and TreeView software (Stanford University, Stanford, CA).

Statistical Analysis {#s2d}
--------------------

### Unsupervised Analysis {#s2d1}

For this analysis, a low-stringency filtering was applied, selecting the genes differentially expressed in 80% of all experiments with a \>3 fold change ratio in at least one experiment. 8,210 genes were selected for the analysis including the five groups of analyzed samples the HCV-related HCC, their non-HCC counterpart, metastasis, and their non metastatic counterpart as well as samples from the normal controls. Hierarchical cluster analysis was conducted on these genes according to Eisen et al. [@pone.0056153-Eisen1], differential expressed genes were visualized by Treeview and displayed according to the central method [@pone.0056153-Ross1]. Principal component analysis (PCA) was applied for visualization when relevant based on the complete dataset.

### Supervised Analysis {#s2d2}

Supervised class comparison was performed using the BRB ArrayTool developed at NCI, Biometric Research Branch, Division of Cancer Treatment and Diagnosis. Three subsets of genes were explored. The first subset included genes up-regulated in HCV-related HCC compared to normal control samples, the second subset included genes up-regulated in the HCV-related non-HCC counterpart compared with normal control samples, the third subset included genes up-regulated in metastasis compared with normal control samples. Paired samples were analyzed using a two-tailed paired Student's *t*-Test. Unpaired samples were tested with a two-tailed unpaired Student's *t*-Test assuming unequal variance or with an *F*-test as appropriate. All analyses were tested for an univariate significance threshold set at a *p*-value \<0.01. Gene clusters identified by the univariate *t*-test were challenged with two alternative additional tests, a univariate permutation test (PT) and a global multivariate PT. The multivariate PT was calibrated to restrict the false discovery rate to 10%. Genes, identified by univariate *t*-test as differentially expressed (*p*-value \<0.01) and a PT significance \<0.05, were considered truly differentially expressed. Gene function was assigned based on Database for Annotation, Visualization and Integrated Discovery (DAVID) and Gene Ontology (<http://www.geneontology.org/>).

### Time course analysis {#s2d3}

A time course analysis was performed to identify markers of tumoral progression between normal liver samples, HCV-related non HCC and HCV-related HCC liver samples. For this analysis, normal liver samples (CTR) were taken as the early time point, HCV-related non HCC as the intermediate point and the HCV-related HCC as the last time point. Parameters for gene selection were: *F* test *p*-value \<0.005, 80% presence call, ratio of \>2 and false discovery rate \<0.1.

### Ingenuity pathway analysis IPA) {#s2d4}

Pathway analysis was performed using the gene set expression comparison kit implemented in BRB-Array- Tools. The human pathway lists determined by "Ingenuity System Database" was selected. Significance threshold of *t*-test was set at 0.01. IPA is a system that transforms large dataset into a group of relevant networks containing direct and indirect relationships between genes based on known interactions in the literature. The significance of each network was estimated by the scoring system provided by Ingenuity. The scores are determined by the number of differentially expressed genes within each of the networks and the strength of the associations among network members.

Results {#s3}
=======

Genes Differentially Expressed among Distinct Tissues {#s3a}
-----------------------------------------------------

The gene expression profile- of tissue samples from the various groups (HCV-related HCC, non-HCC counterpart, metastases, non-metastatic counterpart and controls from healthy donors) were compared by unsupervised analysis. Genes were filtered according to the following criteria: presence in 80% of all experiments, a \>3 fold change ratio in at least one experiment; this filter yielded 8,210 genes that were used for clustering. The HCC and the metastatic samples prevalently clustered into distinct groups, based on differences in their patterns of gene expression (Figure2A). PCA segregated the different sample types into four-five groups according on their pathological status. Statistical and functional analysis of the profiles identified a set of genes whose expression was differentially altered between the groups ([Figure 2B](#pone-0056153-g002){ref-type="fig"}). The expression pattern of gastrointestinal liver metastases was clearly distinct from that of HCV-related primary HCC, allowing a definite molecular characterization of the two diseases.

![Unsupervised hierarchical clustering: Panel A.\
Heat map based on 8,210 genes of 71 liver samples (HCV-related HCC, non-HCC counterpart, metastases, non cancerous counterpart and controls from healthy donors). Genes were filtered according to the following criteria: presence in 80% of all experiments, a \>3 fold change ratio in at least one experiment. Red indicates over-expression; green indicates under-expression; black indicates unchanged expression; gray indicates no detection of expression (intensity of both Cy3 and Cy5 below the cutoff value). Each row represents a single gene; each column represents a single sample. The dendrogram at the top of the matrix indicates the degree of similarity between samples. **Panel B** Principal Component Analysis (PCA) 3D view for gene expression profiles from 71 liver samples. The PCA is based on log2 ratios and the expression profiles are across all the 36,000 genes in the microarrays. The green, blue, red, purple, and orange dots indicate metastasis, HCV-related HCC, HCV related non HCC, non metastatic counterpart, HCV-negative normal control and samples, respectively.](pone.0056153.g002){#pone-0056153-g002}

Differential Gene Expression Patterns between HCV positive Liver Tissue with and without HCC, Metastasis and Normal control Liver Tissue {#s3b}
----------------------------------------------------------------------------------------------------------------------------------------

An unpaired Student's t-test with a cut-off p value set at p\<0.01 comparing HCV-related HCC to normal controls indentified 1864 genes differentially expressed. Among them, 993 were up-regulated and 871 down-regulated in HCV-related HCCs ([Figure 3A](#pone-0056153-g003){ref-type="fig"}).

![Heat map of the genes differentially expressed: identified by Class Comparison Analysis.\
Analysis including HCV-related HCC and normal liver samples from control subjects (**Panel A**)**;** analysis including HCV-related non-HCC liver tissues and liver samples from control subjects (**Panel B**)**;** analysis including liver metastasis and liver samples from control subjects (**Panel C**); analysis including HCV-related HCC and their HCV-positive/cirrhotic counterpart (**Panel D**); analysis including all HCV-related HCC, their HCV-positive/cirrhotic counterpart and normal liver samples, each column represents the average of all samples belonging to the same group as it was a single array (**Panel E**)**.** The expression pattern of the genes is shown, each row representing a single gene.](pone.0056153.g003){#pone-0056153-g003}

In total 198 genes showing up regulation were found in common with our previous study [@pone.0056153-DeGiorgi1], the results is presented as two-way Venn diagram in additional [Figure S1A](#pone.0056153.s001){ref-type="supplementary-material"} and Supplemental [Table S1](#pone.0056153.s002){ref-type="supplementary-material"}. The common genes 2.0 fold upregulated (ranked according to the name) are listed in [Table 1](#pone-0056153-t001){ref-type="table"}.

10.1371/journal.pone.0056153.t001

###### Gene Set Characterizing HCV related HCC Samples.

![](pone.0056153.t001){#pone-0056153-t001-1}

                                                                                       First Dataset   Second Dataset             
  ----------- ---------- ------------------------------------------------------------ --------------- ---------------- ---------- ------
  Hs.437126    ARHGAP9                 Rho GTPase activating protein 9                   0.000778           3.26        0.000521   2.27
  Hs.127799     BIRC3                Baculoviral IAP repeat-containing 3                 0.007263           2.30        0.000341   2.12
  Hs.488143     BLVRA                       Biliverdin reductase A                       0.001564           2.34        0.006145   2.20
  Hs.143733     CCDC34                 Coiled-coil domain containing 34                  0.009417           2.02        0.003457   2.11
  Hs.173724      CKB                        Creatine kinase, brain                        0.00582           2.45        0.000255   2.36
  Hs.713537      GPC3                             Glypican 3                             0.005205           3.32        0.006609   2.82
  Hs.488189     H2AFV                    H2A histone family, member V                    2.50E−05           2.42        0.000491   2.33
  Hs.519972     HLA-F            Major histocompatibility complex, class I, F            0.003041           2.18        0.001327   2.18
  Hs.380250     IFI16               Interferon, gamma-inducible protein 16               0.008685           2.65        2.48E−08   2.69
  Hs.532634     IFI27               Interferon, alpha-inducible protein 27               7.06E−05           3.43        0.000336   4.98
  Hs.458485     ISG15                   ISG15 ubiquitin-like modifier                    0.004877           3.46        0.005316   5.00
  Hs.535903      JRK                            Jerky homolog                            0.002148           2.24        1.21E−05   2.40
  Hs.107125     PLVAP               Plasmalemma vesicle associated protein               0.009883           2.48        0.004255   2.21
  Hs.658434     PSIP1                PC4 and SFRS1 interacting protein 1                 0.000938           3.08        1.59E−06   3.54
  Hs.654402      RELB        V-rel reticuloendotheliosis viral oncogene homolog B        0.002434           2.06        0.000175   2.25
  Hs.381167    SERPINB1                   Serpin peptidase inhibitor                     0.002656           2.19        0.000266   2.13
  Hs.327527    SMARCA4                         SWI/SNF related                           0.006768           2.02        0.002634   2.16
  Hs.708051     STAT1     Signal transducer and activator of transcription 1, 91 kDa     1.58E−06           4.03        0.000374   3.02
  Hs.352018      TAP1                Transporter 1, ATP-binding cassette                 0.002018           2.34        0.000257   2.67
  Hs.653181      THY1                     Thy-1 cell surface antigen                      0.00094           4.89        0.005523   3.24
  Hs.515122      TK1                          Thymidine kinase 1                         0.002458           2.82        0.000584   2.21
  Hs.714406      UBD                             Ubiquitin D                             0.002593           3.72        0.000516   3.80

Comparison between liver tissues from HCV-related non HCC and normal controls (p\<0.01) indentifies 1526 genes differentially expressed. Among them, 618 were up-regulated and 918 down-regulated in HCV-related HCC liver tissues ([Figure 3B](#pone-0056153-g003){ref-type="fig"}). In total 59 genes showing up regulation were found in common with our previous study [@pone.0056153-DeGiorgi1], the results is presented as two-way Venn diagram in additional [Figure S1B](#pone.0056153.s001){ref-type="supplementary-material"} and Supplemental [Table S1](#pone.0056153.s002){ref-type="supplementary-material"}. The common genes 2.0 fold upregulated (ranked according to the name) are listed in [Table 2](#pone-0056153-t002){ref-type="table"}.

10.1371/journal.pone.0056153.t002

###### Gene Set Characterizing HCV related non HCC Samples.

![](pone.0056153.t002){#pone-0056153-t002-2}

                                                                                                       First Dataset   Second Dataset             
  ----------- ---------- ---------------------------------------------------------------------------- --------------- ---------------- ---------- ------
  Hs.497399     ARL8A                          ADP-ribosylation factor-like 8A                           0.000161           2.51        0.006094   2.66
  Hs.496983      HCG4                                HLA complex group 4                                 3.64E−05           2.49        7.40E−06   2.07
  Hs.529317     HERC6                               Hect domain and RLD 6                                5.20E−05           2.28        0.001327   2.14
  Hs.591798    HLA-DQA2             Major histocompatibility complex, class II, DQ alpha 2               0.006389           2.03        0.005283   2.01
  Hs.519972     HLA-F                    Major histocompatibility complex, class I, F                    4.84E−05           3.02        0.000372   2.33
  Hs.512152     HLA-G                    Major histocompatibility complex, class I, G                    0.001323           2.09        0.001857   5.44
  Hs.655226     HLA-H                     Major histocompatibility complex, class I                      0.000177           2.53        0.000776   2.24
  Hs.532634     IFI27                       Interferon, alpha-inducible protein 27                       5.25E−07           5.12        0.008629   3.37
  Hs.523847      IFI6                       Interferon, alpha-inducible protein 6                        0.000191           3.95        0.006532   3.81
  Hs.458485     ISG15                           ISG15 ubiquitin-like modifier                            0.000179           5.59        0.000515   6.69
  Hs.479384    KIAA0746                                KIAA0746 protein                                  0.001081           2.37        0.002704   2.10
  Hs.517307      MX1      Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78     0.001325           3.09        3.40E−06   6.02
  Hs.524760      OAS1                   2\',5\'-oligoadenylate synthetase 1, 40/46 kDa                   0.000247           2.73        0.001017   2.56
  Hs.118633      OASL                      2\'--5\'-oligoadenylate synthetase-like                       0.000174           2.77        0.000355   3.29
  Hs.708051     STAT1             Signal transducer and activator of transcription 1, 91 kDa             7.86E−09           6.04        0.000204   4.51
  Hs.352018      TAP1            Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)             0.000245           2.86        9.60E−05   2.83
  Hs.714406      UBD                                     Ubiquitin D                                     0.002371           3.69        0.002236   2.83
  Hs.38260      USP18                          Ubiquitin specific peptidase 18                           0.008324           2.13        0.006233   2.49

Comparison between liver tissues from HCV-related HCC and parental HCV-related non HCC (p\<0.01) indentifies 1020 genes differentially expressed. Among them, 468 were up-regulated and 552 down-regulated in HCV-related HCC liver tissues ([Figure 3C](#pone-0056153-g003){ref-type="fig"}).

In total 10 genes showing up regulation were found in common with our previous study [@pone.0056153-DeGiorgi1], the results is presented as two-way Venn diagram in additional [Figure S1C](#pone.0056153.s001){ref-type="supplementary-material"} and Supplemental [Table S1](#pone.0056153.s002){ref-type="supplementary-material"}. The common genes 2.0 fold upregulated (ranked according to the name) are listed [Table 3](#pone-0056153-t003){ref-type="table"}.

10.1371/journal.pone.0056153.t003

###### Gene Set Characterizing HCC Samples compared with autologous tissue.

![](pone.0056153.t003){#pone-0056153-t003-3}

                                                                             First Dataset   Second Dataset             
  ----------- -------- ---------------------------------------------------- --------------- ---------------- ---------- ------
  Hs.440961     CAST                       Calpastatin                         0.009947           1.64        4.79E−06   1.58
  Hs.93836     DFNB31            Deafness, autosomal recessive 31              0.008123           1.54        0.002648   1.57
  Hs.22785     GABRE    Gamma-aminobutyric acid (GABA) A receptor, epsilon     0.002371           2.12        0.005056   3.41
  Hs.488189    H2AFV               H2A histone family, member V                0.001511           1.72        2.31E−05   1.62
  Hs.485938    RRAGD                Ras-related GTP binding D                  0.000427           1.73        0.000292   1.66
  Hs.407856    SPINK1        Serine peptidase inhibitor, Kazal type 1          5.31E−06          14.49        0.002134   4.12
  Hs.164070    THEM4            Thioesterase superfamily member 4              0.008042           1.57        0.000359   1.61

Comparison of liver tissues from metastases and normal controls (*p\<0.01)* indentified 1,780 genes. Among them, 760 were shown to be up-regulated and 860 down-regulated in metastatic liver tissues ([Figure 3D](#pone-0056153-g003){ref-type="fig"} and Supplemental [Table S2](#pone.0056153.s003){ref-type="supplementary-material"}). The genes showing the highest fold up-regulation are listed in [Table 4](#pone-0056153-t004){ref-type="table"}.

10.1371/journal.pone.0056153.t004

###### Gene Set Characterizing Metastatic Samples.

![](pone.0056153.t004){#pone-0056153-t004-4}

  UGCluster    Gene Name                           Description                            p-value     Fold-Change
  ----------- ----------- ------------------------------------------------------------- ------------ -------------
  Hs.529353      ACSS1           Acyl-CoA synthetase short-chain family member 1          3.99E−08       4.40
  Hs.514581      ACTG1                           Actin, gamma 1                           2.01E−08       3.32
  Hs.530009      AGR2                      Anterior gradient homolog 2                   0.00026377      3.89
  Hs.270833      AREG                             Amphiregulin                            3.82E−05       3.82
  Hs.701324     ARHGAP4                  Rho GTPase activating protein 4                  1.01E−07       2.59
  Hs.371889     ATP1A1          ATPase, Na+/K+ transporting, alpha 1 polypeptide          6.78E−08       2.98
  Hs.591382       BSG                                Basigin                              1.05E−07       2.93
  Hs.8859        CANT1                  Calcium activated nucleotidase 1                  8.44E−06       2.90
  Hs.523852      CCND1                              Cyclin D1                             7.16E−06       3.28
  Hs.82916       CCT6A           Chaperonin containing TCP1, subunit 6A (zeta 1)          1.06E−08        4.3
  Hs.502328      CD44                             CD44 molecule                          0.00033064      2.16
  Hs.114286       CD9                             CD9 molecule                            4.99E−07       3.53
  Hs.709226      CDH3                    Cadherin 3, type 1, P-cadherin                   2.32E−07       3.37
  Hs.712603      CENPO                        Centromere protein O                        4.28E−09       2.92
  Hs.173724       CKB                        Creatine kinase, brain                       7.68E−09       5.14
  Hs.414565      CLIC1                  Chloride intracellular channel 1                  4.93E−07       3.23
  Hs.443625     COL3A1                     Collagen, type III, alpha 1                    8.67E−07       6.38
  Hs.17441      COL4A1                     Collagen, type IV, alpha 1                     1.20E−06       5.41
  Hs.570065     COL4A3          Collagen, type IV, alpha 3 (Goodpasture antigen)         0.00010556      3.13
  Hs.2242        CSN2                              Casein beta                            1.69E−05       3.20
  Hs.67928       ELF3                           E74-like factor 3                         1.60E−05       3.01
  Hs.655278     FER1L3                       Fer-1-like 3, myoferlin                      4.01E−08       2.86
  Hs.443687      FHL2                     Four and a half LIM domains 2                   1.35E−05       3.20
  Hs.499659     GARNL4             GTPase activating Rap/RanGAP domain-like 4             2.00E−07       4.21
  Hs.203699     GOLPH3L                    Golgi phosphoprotein 3-like                    6.84E−09       12.95
  Hs.231320     GPR160                   G protein-coupled receptor 160                   4.64E−08       3.70
  Hs.2704        GPX2                       Glutathione peroxidase 2                      4.41E−06       2.81
  Hs.523836      GSTP1                    Glutathione S-transferase pi                    2.26E−07       6.93
  Hs.31720       HEPH                              Hephaestin                             1.35E−05       3.96
  Hs.594238      KPNA2        Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)       0.00037649      2.15
  Hs.406013      KRT18                             Keratin 18                             1.74E−06       5.81
  Hs.374191     LEPREL1                          Leprecan-like 1                          3.36E−05       10.35
  Hs.5302       LGALS4        Lectin, galactoside-binding, soluble, 4 (galectin 4)        2.74E−05       2.59
  Hs.444118      MCM6            Minichromosome maintenance complex component 6           7.33E−09       2.66
  Hs.632177       MVP                          Major vault protein                        6.08E−07       2.59
  Hs.533282      NONO              Non-POU domain containing, octamer-binding             4.45E−08       2.55
  Hs.406515      NQO1                   NAD(P)H dehydrogenase, quinone 1                 0.00017945      9.82
  Hs.553765     OR4K17        Olfactory receptor, family 4, subfamily K, member 17        3.42E−05       3.57
  Hs.154104     PLAGL2                  Pleiomorphic adenoma gene-like 2                  2.41E−08       2.50
  Hs.155342      PRKCD                       Protein kinase C, delta                      4.30E−08       2.52
  Hs.499094     PYCARD                   PYD and CARD domain containing                   6.41E−07       2.52
  Hs.714383    RAPGEFL1        Rap guanine nucleotide exchange factor (GEF)-like 1       0.00091543      2.67
  Hs.449968      RHCE                     Rh blood group, CcEe antigens                  0.00022816      3.64
  Hs.653288      RNF12                       Ring finger protein 12                       7.53E−09       2.78
  Hs.381061      RPL19                        Ribosomal protein L19                       2.49E−08       2.77
  Hs.514196      RPL27                        Ribosomal protein L27                       1.36E−08       2.63
  Hs.178551      RPL8                         Ribosomal protein L8                        3.73E−07       2.56
  Hs.356502      RPLP1                    Ribosomal protein, large, P1                    2.73E−07       2.88
  Hs.118076      RPS4X                   Ribosomal protein S4, X-linked                   1.03E−08       2.51
  Hs.546287      RPS7                         Ribosomal protein S7                        6.38E−06       2.91
  Hs.449909      RPSA                         Ribosomal protein SA                        1.02E−08       2.61
  Hs.381167    SERPINB1                    Serpin peptidase inhibitor                     2.56E−09       3.70
  Hs.111779      SPARC        Secreted protein, acidic, cysteine-rich (osteonectin)       1.69E−07       2.87
  Hs.31439      SPINT2             Serine peptidase inhibitor, Kunitz type, 2             1.44E−08       3.46
  Hs.643338     SPOCK1                          Sparc/osteonectin                        0.00063078      3.91
  Hs.352018      TAP1      Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)    4.87E−06       2.68
  Hs.12956      TAX1BP3    Tax1 (human T-cell leukemia virus type I) binding protein 3    1.03E−05       2.76
  Hs.529618      TFRC                   Transferrin receptor (p90, CD71)                  2.13E−05       2.81
  Hs.529618      TFRC                   Transferrin receptor (p90, CD71)                  2.13E−05       2.81
  Hs.522632      TIMP1                  TIMP metallopeptidase inhibitor 1                 5.26E−08       4.92
  Hs.515122       TK1                      Thymidine kinase 1, soluble                    1.51E−07       4.03
  Hs.89643        TKT              Transketolase (Wernicke-Korsakoff syndrome)           0.00026987      2.93
  Hs.513058      TMED3      Transmembrane emp24 protein transport domain containing 3     2.34E−07       3.28
  Hs.46720      TMPRSS5                      Transmembrane protease                       8.05E−05       2.50
  Hs.446574     TMSB10                          Thymosin beta 10                          2.65E−07       2.91
  Hs.370515      TRIM5                    Tripartite motif-containing 5                   1.17E−06       2.71
  Hs.654595      VIL1                               Villin 1                              2.17E−05       3.08
  Hs.128548       VIM                          WD repeat domain 1                         4.79E−05       2.57
  Hs.301094     ZNF629                       Zinc finger protein 629                      6.47E−05       2.58

Gene Signatures Involved in HCC progression {#s3c}
-------------------------------------------

A progression of differences in gene expression across tissue types from normal (n  = 6) to HCV related non HCC (n  = 19) to HCV-related HCC (n  = 18) identified 450 genes with decreasing and 136 genes with increasing trend in expression ([Figure 3E](#pone-0056153-g003){ref-type="fig"}). Genes with a significantly increasing trend in expression values were considered as possible diagnostic and prognostic markers. The genes showing the highest fold of up-regulation that were also consistent with our previous findings [@pone.0056153-DeGiorgi1] are reported in [Table 5](#pone-0056153-t005){ref-type="table"}.

10.1371/journal.pone.0056153.t005

###### Gene-signature of HCC progression.
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  UGCluster                                         Name                                         Symbol
  ----------- -------------------------------------------------------------------------------- ----------
  Hs.654433                Alcohol dehydrogenase 1A (class I), alpha polypeptide                 ADH1A
  Hs.477887                           Angiotensin II receptor, type 1                            AGTR1
  Hs.116724                       Aldo-keto reductase family 1, member B10                      AKR1B10
  Hs.9613                                   Angiopoietin-like 4                                 ANGPTL4
  Hs.374774                               Ankyrin repeat domain 29                              ANKRD29
  Hs.633003                                  Apolipoprotein A-I                                  APOA1
  Hs.440934                                   Arginase, liver                                     ARG1
  Hs.486031                  Activating signal cointegrator 1 complex subunit 3                  ASCC3
  Hs.98338                                    Aurora kinase C                                    AURKC
  Hs.80756                         Betaine-homocysteine methyltransferase                         BHMT
  Hs.356440                           Coiled-coil domain containing 72                           CCDC72
  Hs.575869                            Complement factor H-related 1                             CFHR1
  Hs.591464                                       Cingulin                                        CGN
  Hs.268326                       C-type lectin domain family 2, member D                        CLEC2D
  Hs.220649                        C-type lectin superfamily 4, member G                         CLEC4G
  Hs.172928                              Collagen, type I, alpha 1                               COL1A1
  Hs.508716                              Collagen, type IV, alpha 2                              COL4A2
  Hs.522891                          Chemokine (C-X-C motif) ligand 12                           CXCL12
  Hs.590921                           Chemokine (C-X-C motif) ligand 2                           CXCL2
  Hs.706262                                       Decorin                                         DCN
  Hs.476453                              Deoxyribonuclease I-like 3                             DNASE1L3
  Hs.80552                                     Dermatopontin                                      DPT
  Hs.224171                               Enolase 3 (beta, muscle)                                ENO3
  Hs.27836                        Fibronectin type III domain containing 4                       FNDC4
  Hs.25647                  V-fos FBJ murine osteosarcoma viral oncogene homolog                  FOS
  Hs.78619                                Gamma-glutamyl hydrolase                                GGH
  Hs.518525                               Glutamate-ammonia ligase                                GLUL
  Hs.713537                                      Glypican 3                                       GPC3
  Hs.190783                               Histidine ammonia-lyase                                 HAL
  Hs.190783                               Histidine ammonia-lyase                                 HAL
  Hs.659767                                Hydroxyacid oxidase 2                                  HAO2
  Hs.59889                    3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2                   HMGCS2
  Hs.532634                        Interferon, alpha-inducible protein 27                        IFI27
  Hs.523414                     Insulin-like growth factor 2 (somatomedin A)                      IGF2
  Hs.709180                               Netrin 2-like (chicken)                                 IGKC
  Hs.632629                         Indolethylamine N-methyltransferase                           INMT
  Hs.657894                                IQ motif containing H                                  IQCH
  Hs.458485                            ISG15 ubiquitin-like modifier                             ISG15
  Hs.76716                          Inter-alpha (globulin) inhibitor H3                          ITIH3
  Hs.77741                                      Kininogen 1                                       KNG1
  Hs.77741                                      Kininogen 1                                       KNG1
  Hs.492314                  Lysosomal associated protein transmembrane 4 beta                  LAPTM4B
  Hs.130767                          Leucine rich repeat containing 46                           LRRC46
  Hs.482087                  Leucine rich repeat containing 8 family, member D                   LRRC8D
  Hs.514402                                 Protein kinase LYK5                                   LYK5
  Hs.201083                        Mal, T-cell differentiation protein 2                          MAL2
  Hs.349110               Macrophage stimulating 1 (hepatocyte growth factor-like)                MST1
  Hs.512587               Macrophage stimulating 1 (hepatocyte growth factor-like)                MST1
  Hs.512973               Protein tyrosine phosphatase-like A domain containing 1               PTPLAD1
  Hs.334587                      RNA binding protein with multiple splicing                      RBPMS
  Hs.375142                Ral guanine nucleotide dissociation stimulator-like 3                  RGL3
  Hs.633703                               Ring finger protein 125                                RNF125
  Hs.558396                     Stearoyl-CoA desaturase (delta-9-desaturase)                      SCD
  Hs.275775                              Selenoprotein P, plasma, 1                              SEPP1
  Hs.702168                                Shroom family member 3                               SHROOM3
  Hs.167584         Solute carrier family 2 (facilitated glucose transporter), member 2          SLC2A2
  Hs.407856                       Serine peptidase inhibitor, Kazal type 1                       SPINK1
  Hs.708051              Signal transducer and activator of transcription 1, 91kDa               STAT1
  Hs.333132                              Tudor domain containing 1                               TDRD1
  Hs.516578    Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)     TFPI
  Hs.653181                              Thy-1 cell surface antigen                               THY1
  Hs.184194                        Transmembrane 4 L six family member 5                         TM4SF5
  Hs.596726                              Transmembrane protein 106C                             TMEM106C
  Hs.85524                             Tripartite motif-containing 55                            TRIM55
  Hs.714406                                     Ubiquitin D                                       UBD

Canonical Pathways and Molecular and Cellular Functions {#s3d}
-------------------------------------------------------

To explore the biological significance of the genes characterizing different pathological or normal conditions we investigated their interactions by IPA mapping their molecular/cellular functions and canonical pathways. The more important molecular and cellular functions (ranked according to lowest *p* value) of genes up-regulated in HCV-related HCC samples were related to regulation of gene expression (1.12E−17 to 3.41E−03), cellular growth and proliferation (2.00E−14 to 3.84E−03) and post-translational modification (1.53E−09 to 2.45E−03). The top canonical pathways included protein ubiquitination (*p* = 2.88E−03), 14-3-3 mediated Signaling (p = 1.13-E02) and Aryl Hydrocarbon receptor signaling pathway (*p* = 3.09E-02) ([Figure 4A](#pone-0056153-g004){ref-type="fig"}). The more important molecular and cellular functions (High *p* value) of genes up-regulated in HCV-related non HCC samples were related to Cellular Growth and Proliferation (1.04E-22 to 4.61E−04), Gene Expression (2.07E−22 to 4.58E−04) and Cell-To-Cell Signaling and Interaction (9.05E−14 to 4.65E−04)**.** The top canonical pathways included Interferon Signaling Genes (*p* = 9.78E−04), Antigen Presentation Pathway (p = 1.58E−03) and Protein Ubiquitination Pathway (p = 2.44E−02) ([Figure 4B](#pone-0056153-g004){ref-type="fig"}).

![Ingenuity Pathways analysis: significant pathways at the nominal 0.01 level of the unpaired Student\'s t-test.\
The 3 top-scoring pathways of genes up regulated in HCV-related HCC (**Panel A**), in HCV related non HCC (**Panel B**) and in Metastatic liver samples (**Panel C**).](pone.0056153.g004){#pone-0056153-g004}

The more important molecular and cellular functions (High *p* value) of genes up-regulated in metastases were related to Gene Expression (6.08E−26 to 2.00E−04), Cellular Growth and Proliferation (1.86E−25 to 8.64E−05), Cell Cycle (5.67E−21 to 1.33E−04). The top canonical pathways included Arginine and Proline Metabolism (p = 1.77E−09), Coagulation System (p = 9.68E−09) and Acute Phase Response Signaling (p = 2.08E−08) ([Figure 4C](#pone-0056153-g004){ref-type="fig"}). [Table 6](#pone-0056153-t006){ref-type="table"} summarizes the more important findings for each of the described comparison analysis.

10.1371/journal.pone.0056153.t006
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                                                                                                                                 HCV related HCC tissues versusnormal livers                                                       HCV related non HCC tissuesversus normal livers                                                          Metastatic liver tissues versus normal livers
  ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------
  Number of differentially expressed genes Associated Network Functions (five top-scored network)                 1\. Connective Tissue Disorders, Developmental Disorder, Genetic Disorder                              1\. Inflammatory Disease, Inflammatory Response, Renal Inflammation                                  1\. Cellular Assembly and Organization, Genetic Disorder, Lipid Metabolism
                                                                                                            2\. Cell Cycle, Cellular Assembly and Organization, Cellular Function and Maintenance                               2\. Cancer, Gastrointestinal Disease, Gene Expression                                       2\. Cellular Growth and Proliferation, Genetic Disorder, Neurological Disease
                                                                                                                   3\. Cancer, Reproductive System Disease, Skeletal and Muscular Disorders                        3\. Cellular Development, Tissue Development, Cellular Growth and Proliferation                                 3\. Developmental Disorder, Genetic Disorder, Metabolic Disease
                                                                                                     4\. DNA Replication, Recombination, and Repair, Nucleic Acid Metabolism, Small Molecule Biochemistry   4\. Cell Cycle, Cellular Assembly and Organization, DNA Replication, Recombination, and Repair              4\. Cellular Function and Maintenance, Post-Translational Modification, Cell Signaling
                                                                                                            5\. RNA Damage and Repair, RNA Post-Transcriptional Modification, Molecular Transport                     5\. Cell Cycle, Cellular Movement,Endocrine System Developmentand Function             5\. RNA Post-Transcriptional Modification, DNA Replication, Recombination, and Repair, Amino Acid Metabolism
  Top molecular and cellular Function                                                                                         Gene Expression (1.12E−17 to 3.41E−03) 1074 genes;                                         Cellular Growth and Proliferation (1.04E−22 to 4.61E−04) 1353 genes;                                             Gene Expression (6.08E−26 to 2.00E−04) 1299 genes;
                                                                                                                     Cellular Growth and Proliferation(2.00E−14 to 3.84E−03) 1328 genes;                                          Gene Expression (2.07E−22 to4.58E−04) 1066 genes;                                              Cellular Growth and Proliferation (1.86E−25 to 8.64E−05) 1623 genes;
                                                                                                                       Post-Translational Modification (1.53E−09to 2.45E−03) 523 genes;                                Cell-To-Cell Signaling and Interaction (9.05E−14 to 4.65E−04) 681 genes;                                              Cell Cycle (5.67E−21 to 1.33E−04) 818 genes;
                                                                                                                                 Cell Cycle (1.94E−08 to 3.81E−03) 624 genes;                                                        Cell Death (3.94E−13 to 4.59E−04)1032 genes;                                                        Cellular Movement (6.06E−21 to 2.17E−04) 911 genes;
                                                                                                                              Cell Morphology (4.44E−08 to 4.22E−03) 393 genes;                                                   Cellular Movement (1.43E−12 to4.80E−04) 745 genes;                                                        Cell Death (9.05E−18 to 1.71E−04) 1266 genes;
  Top canonical pathways                                                                                                        Protein Ubiquitination Pathway (p = 2.88E−03);                                                           Interferon Signaling (p = 9.78E−04);                                                              Arginine and Proline Metabolism (p = 1.77E−09);
                                                                                                                                  14-3-3 mediated Signaling (p = 1.13-E02);                                                          Antigen Presentation Pathway (p = 1.58E−03);                                                                 Coagulation System(p = 9.68E−09);
                                                                                                                              Aryl Hydrocarbon receptor signaling (p = 3.09E−02)                                                    Protein Ubiquitination Pathway (p = 2.44E−02)                                                           Acute Phase Response Signaling (p = 2.08E−08)

Among the three different class comparison analysis (HCV-related HCC, HCV-related non HCC and Metastatic liver tissue vs normal control) we found a gene-set that distinguish the different cases of liver disease, in particular with time course analysis we identify the genes that should be candidate as a possible progression markers ([Figure 5](#pone-0056153-g005){ref-type="fig"}).

![Molecular signatures in Human Liver Cancer: Hierarchical clustering of the potentially gene markers up-regulated in: Panel A, HCV-related HCC liver samples (left panel first dataset, right panel second dataset); Panel B, HCV-related non HCC liver samples (left panel first dataset, right panel second dataset); Panel C, HCV-related HCC; Panel D, metastatic liver samples; Panel E, genes up-regulated considered possible markers of tumor progression.](pone.0056153.g005){#pone-0056153-g005}

Discussion {#s4}
==========

HCC is a common and aggressive malignant tumor worldwide with a dismal outcome. Early detection and resection may offer an opportunity to improve the long-term survival for HCC patients. Unfortunately, with current diagnostic approaches, only about 10% to 20% of HCC patients are eligible for resection [@pone.0056153-Lai1]. In the first study, microarray analyses of liver biopsies from HCC nodules and paired non-adjacent non-HCC liver tissue of the same HCV-positive patients were compared to biopsies from HCV-negative control subjects. The class comparison analysis used in that study successfully identified a set of genes significant differentially expressed. Moreover the up-regulated genes identified within the individual class comparison analysis were evaluated and classified by a pathway analysis, according to the \"Ingenuity System Database\".

The genes up-regulated in samples from HCV-related HCC were classified in metabolic pathways, and the most represented are the Aryl Hydrocarbon receptor signaling (AHR) and, protein Ubiquitination pathways, which have been previously reported to be involved in cancer, and in particular in HCC, progression. The genes up-regulated in samples from HCV-related non-HCC tissue were classified in several pathways prevalently associated to inflammation and native/adaptive immunity and most of the over expressed genes belong to the Antigen Presentation pathway. In this new study we performed the same statistical analysis under the same condition to confirm our previous data. To elucidate the genes and molecular pathways involved in the HCV-related HCC a class comparisons analysis were performed on new samples set. This analysis allowed us to identify the unique probe sets characterizing the pathological status, in fact as expected, the gene expression patterns were found to vary significantly among the HCC and normal control liver samples. Genes associated with cell death, cell to cell signaling and interaction, were found to have increased expression in HCC samples. The molecular events linked to the development and progressions of HCC are not well known. Malignant hepatocytes are the result of sequential changes accumulated in mature hepatocytes or can derive from stem cells. The most accepted hypotheses [@pone.0056153-Buendia2], [@pone.0056153-Thorgeirsson1] describes a step-by-step process in which external stimuli induce genetic alterations in mature hepatocytes leading to cell death, cellular proliferation, and the production of monoclonal populations. These populations harbor dysplastic hepatocytes that evolve to dysplastic nodules [@pone.0056153-Theise1].

Canonical pathways prevalently associated with HCV-related HCC included protein ubiquitination, antigen presentation and Aryl Hydrocarbon receptor signaling pathway, confirming our previous data.

Cellular growth and proliferation and antigen presentation were the more important cellular and molecular functions when HCV-related non HCC samples were compared with normal control liver tissue. These data agree with the numerous regulatory roles reported for the HCV core, that affect signal transduction, expression of viral and cellular genes, cell growth and proliferation [@pone.0056153-Lohmann1], [@pone.0056153-Blight1].

Several viruses target specific components of the MHC class I pathway, leading to diminished cell surface expression of MHC class I molecules. Other viruses block the transport of MHC class I molecules through the endoplasmic reticulum (ER), inhibit TAP-mediated translocation of cytoplasmic peptides into the ER, or interfere with proteasomal degradation of their own proteins [@pone.0056153-Rosenberg1]. Other viruses, like human cytomegalovirus, escape CD8_T-cell recognition by downregulating cellular MHC class I molecules [@pone.0056153-Falk1] and simultaneously inducing the expression of virus-encoded MHC class I homologues capable of engaging inhibitory receptors that give a negative signal blocking NK cell function. Flaviviruses can up regulate MHC class I cell surface expression by increased peptide supply to the ER [@pone.0056153-Momburg1], [@pone.0056153-Mullbacher1]. Viruses may use these strategies to evade and counteract a potential NK cell attack. Some studies demonstrated that HCV core protein induced the up regulation of antigen presentation and immune response mechanisms [@pone.0056153-Herzer1].

Canonical pathways mainly associated with HCV-related non-HCC tissue included Interferon Signaling, SAPK/JNK Signaling and NF-kB Activation by viruses pathway. These pathways are prevalently associated with inflammation and native/adaptive immunity.

A traditional HCC diagnosis has relied on the use of a single biomarker approach (e.g., AFP).

Advances in gene expression profiling have provided new insights into the molecular genetics of HCC, showing strong expression signatures of cell proliferation and antiapoptosis genes (such as PNCA and cell cycle regulators CDK4, CCNB1, CCNA2, and CKS2) along with genes involving ubiquitination [@pone.0056153-Hoshida1], as well as unique molecular markers of progression like HSP70, CAP2, GPC3, and GS [@pone.0056153-Sakamoto1]. HCC-specific alterations of signal transduction pathways and protein expression patterns have been detected and have led to the development of new therapeutic agents with molecular targets such as EGFR, VEGF, DDEFL, VANGL1, WDRPUH, Ephrin-A1, GPC3, Number gain 7q, PFTK1, PEG10 and miR-122a [@pone.0056153-Zender1]--[@pone.0056153-Gramantieri1].

We based our study on the identification of the minimal set of genes sufficient for the molecular signature and for developing a chip able to contribute or substitute the pathology diagnosis and to furnish a prognostic indication of progression risk, as well as responsivity to pharmacological treatment of HCV-associated hepatitis and their progression to cirrhosis/HCC.

Among the four different class comparison analysis (HCV-related HCC, HCV-related non HCC and Metastatic liver tissue vs. normal control; HCV-related HCC vs. autologous HCV-related non HCC liver tissue) we found a gene-set that distinguish the different cases of liver disease, in particular with time course analysis we identify the genes that should be candidate as a possible progression markers (e.g., GPC3, CXCL12, SPINK1, GLUL, UBD, TM4SF5, DPT, SCD, MAL2, TRIM55, COL4A2). All these data altogether suggested developing a specific gene-chip along with genes showing the highest fold up-regulation in common with previous work representing the different stage of disease.

The identification of the lesions and the evaluation of their neoplastic progression will be based on the gene pattern expression on the gene-chip ([Figure 5](#pone-0056153-g005){ref-type="fig"}, [Table 1](#pone-0056153-t001){ref-type="table"}--[5](#pone-0056153-t005){ref-type="table"}).

In conclusion we identified a set of genes highly candidate as gene signatures to be validate on a larger clinical sample size of liver tissue biopsies to evaluate consistency and universality of the results, to verify the effective power of distinguishing different pathological stage of liver disease and to assess their value as progression markers for early HCC diagnosis in HCV positive patients. Furthermore, identification of specific alterations in key metabolic pathways could give the opportunity to identify new therapeutic targets for innovative, personalized treatments.

Moreover, the gene-expression pattern will be correlated with additional clinical parameters (besides disease stage and tumor histopathology) such as the frequency with which patients show the identified profile, patient age and gender, concurrent diseases and pharmacological treatments.

In parallel, all our liver collection samples will undergo further molecular analysis (which include miRNA, aCGH, proteomic) to develop increasingly sophisticated gene expression indicators of specific types or stages of liver disease as well as responsivity to pharmacological treatment of HCV-associated hepatitis and their progression to cirrhosis/HCC.
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**Venn diagram illustrating the number of up-regulated genes in common between first (green circle) and second (blue circle) data set.** Genes in common are in red circle. A) Comparison analysis between HCV-related HCC versus normal liver. B) Comparison analysis between HCV related non-HCC versus normal liver. C) Comparison analysis between HCV-related HCC versus autologous HCV related non-HCC.
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Click here for additional data file.
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**List of the 198 genes upregulated in HCC samples of the two independent datasets, in comparison to liver control biopsies.**

(XLS)
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Click here for additional data file.

###### 

**List of genes upregulated or down regulated in metastatic liver lesions in comparison to normal liver tissue.**

(XLS)

###### 

Click here for additional data file.
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